Danmark - dansk - SEGES Landbrug & Fødevarer

klarsø a/s - chlormequat-chlorid, chlormequat - vandopløseligt koncentrat - 460 g/l chlormequat-chlorid ; (~ 357 g/l chlormequat

Danmark - dansk - SEGES Landbrug & Fødevarer

danstar ferment ag - clonostachys - vanddispergerbart granulat - 1000000000 cfu/kg clonostachys rosea stamme j1446 (=gliocladium catenulatum stamme j1446)

Danmark - dansk - SEGES Landbrug & Fødevarer

syngenta nordics a/s - abamectin - emulsionskoncentrat - 18 g/l abamectin

Danmark - dansk - SEGES Landbrug & Fødevarer

arysta lifescience great britain ltd. - daminozid - vandopløseligt granulat - 850 g/kg daminozid

Danmark - dansk - SEGES Landbrug & Fødevarer

syngenta nordics a/s - paclobutrazol - suspensionskoncentrat - 4 g/l paclobutrazol

Danmark - dansk - SEGES Landbrug & Fødevarer

lfs kemi - daminozid - vandopløseligt granulat - 850 g/kg daminozid

Den Europæiske Union - dansk - EMA (European Medicines Agency)

laboratorios hipra, s.a. - mycoplasma hyopneumoniae, strain 7304 (nexhyon), expressing the capsid protein of porcine circovirus type 2a, inactivated - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - svin - for the active immunisation of pigs:to reduce lung lesions associated with porcine enzootic pneumonia caused by mycoplasma hyopneumoniae. also, to reduce the incidence of these lesions (as observed in field studies). to reduce viraemia, virus load in lungs and lymphoid tissues and the duration of the viraemic period associated with diseases caused by porcine circovirus type 2 (pcv2). efficacy against pcv2 genotypes a, b and d has been demonstrated in field studies. to reduce culling rate and the loss of daily weight gain caused by mycoplasma hyopneumoniae and/or pcv2 related diseases (as observed at 6 months of age in field studies). mycoplasma hyopneumoniae: onset of immunity: 3 weeks after vaccinationduration of immunity: 23 weeks after vaccinationporcine circovirus type 2:onset of immunity: 2 weeks after vaccinationduration of immunity: 22 weeks after vaccinationin addition, a reduction in nasal and faecal shedding and the duration of nasal excretion of pcv2 was demonstrated in animals challenged at 4 weeks and at 22 weeks after vaccination.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

fatro s.p.a - rabbit hemorrhagic disease virus 2 vp1ab, rabbit hemorrhagic disease virus vp1a - immunologicals for dyr af hareordenen - kaniner - for active immunisation of rabbits from the age of 28 days to reduce mortality, infection, clinical signs and organ lesions of rabbit haemorrhagic disease caused by rhdv1 and rhdv2.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

ceva-phylaxia co. ltd. - live recombinant fowlpox virus expressing the membrane fusion protein and the encapsidation protein of avian infectious laryngotracheitis virus (rfp-lt) and avian encephalomyelitis virus, strain calnek 1143 (ae) - immunologicals for aves, live viral vaccines, domestic fowl - kylling - for active immunisation of chickens of 8 to 13 weeks of age in order to reduce the skin lesions due to fowlpox, to reduce the clinical signs and tracheal lesions due to avian infectious laryngotracheitis and to prevent egg production losses due to avian encephalomyelitis.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

ceva-phylaxia co. ltd. - recombinant fowlpox virus expressing the membrane fusion protein and the encapsidation protein of avian infectious laryngotracheitis virus, live - kylling - for active immunisation of chickens from 8 weeks of age in order to reduce the skin lesions due to fowlpox and to reduce the clinical signs and tracheal lesions due to avian infectious laryngotracheitis.